Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

NCT05136456 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Membranous Nephropathy

Interventions

DRUG: SHR1459 Low Dose
DRUG: SHR1459 High Dose
DRUG: Placebo

Sponsor

Reistone Biopharma Company Limited